Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CytoMed Therapeutics Ltd GDTC

Healthcare Biotechnology
CytoMed Therapeutics Limited is a biopharmaceutical company. It is focused on harnessing its licensed proprietary technologies to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges... see more

Recent & Breaking News (NDAQ:GDTC)

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

GlobeNewswire November 20, 2024

CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

GlobeNewswire October 7, 2024

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank

GlobeNewswire October 3, 2024

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

GlobeNewswire September 30, 2024

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

GlobeNewswire July 17, 2024

CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration

Accesswire March 20, 2024

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

GlobeNewswire March 18, 2024

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

GlobeNewswire March 4, 2024

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

GlobeNewswire January 29, 2024

CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology

PR Newswire December 5, 2023

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update

PR Newswire November 17, 2023

CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

PR Newswire November 14, 2023

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology

Accesswire October 24, 2023

Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology

PR Newswire September 25, 2023

CytoMed Expands Research Collaboration into China After Entering Into MOU

Accesswire August 29, 2023

CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor Summit

Newsfile August 17, 2023

CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency

PR Newswire August 15, 2023

Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

PR Newswire August 1, 2023

A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US

PR Newswire July 6, 2023

CytoMed Therapeutics to Ring Nasdaq Closing Bell

PR Newswire May 11, 2023